Narrowband Imaging for p16+ Unknown Primary Squamous Cell Carcinoma Prior to Transoral Robotic Surgery

Otolaryngol Head Neck Surg. 2020 Dec;163(6):1198-1201. doi: 10.1177/0194599820933204. Epub 2020 Jun 23.

Abstract

Our purpose was to assess the potential utility of narrowband imaging (NBI) as a tool in diagnosing and treating unknown primary oropharyngeal squamous cell carcinoma (OPSCC) in patients prior to diagnostic resection with transoral robotic surgery (TORS). Between 2016 and March 2019, 29 patients with carcinoma of unknown primary meeting inclusion criteria were identified and treated with TORS. NBI was used preoperatively in 9 of 29 patients. A suspected tumor site was delineated by NBI in 8 of 9 patients (89%). Of the patients imaged with NBI, 8 of 9 (89%) patients had a pathologically confirmed tumor following TORS, corresponding to the same 8 suspected tumor sites identified with NBI. In contrast, a primary tumor was localized following TORS in 15 of 20 (75%) patients not evaluated with NBI. Thus, we see NBI as a potentially useful tool for the diagnosis and management of p16+ carcinoma of unknown primary.Level of Evidence: IIb.

Keywords: carcinoma of unknown primary; head and neck squamous cell carcinoma; narrowband imaging; transoral robotic surgery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Squamous Cell / diagnostic imaging*
  • Carcinoma, Squamous Cell / surgery*
  • Cyclin-Dependent Kinase Inhibitor p16
  • Female
  • Humans
  • Male
  • Middle Aged
  • Narrow Band Imaging*
  • Neoplasms, Unknown Primary
  • Oropharyngeal Neoplasms / diagnostic imaging*
  • Oropharyngeal Neoplasms / surgery*
  • Robotic Surgical Procedures*

Substances

  • Cyclin-Dependent Kinase Inhibitor p16